데이터를 보충하는 중입니다. 잠시 후 페이지를 새로 고치면 최신 내용을 볼 수 있습니다
122852-42-0Cc1[nH]cnc1CN1CCc2c(c3ccccc3n2C)C1=OJSWZEAMFRNKZNL-UHFFFAOYSA-NAlosetron is a pyrido[4,3-b]indole compound having a 5-methyl-1H-imidazol-4-ylmethyl group at the 2-position. It has a role as a serotonergic antagonist, an antiemetic and a gastrointestinal drug. It is a member of imidazoles and a pyridoindole.
crystalline powder
안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.
The most common adverse effect associated with alosetron administration is constipation. A randomized, double-blind, placebo-controlled study assessed the efficacy and safety of alosetron 0.5 mg and 1 mg in women with severe IBS-D. The study data revealed that constipation occurred in patients receiving 0.5 mg (9%), 1 mg once daily (16%), and 1 mg twice daily (19%).
Drug-Induced Liver Injury Severity and Toxicity (DILIst)
alosetron
DILI Positive
Oral
DOI:10.1016/j.drudis.2019.09.022
A - Alimentary tract and metabolism
QA - Alimentary tract and metabolism
Alosetron is a potent and selective antagonist of the serotonin 5-HT<sub>3</sub> receptor type. Activation of these receptors and the resulting neuronal depolarization affects the regulation of visceral pain, colonic transit, and GI secretions processes that are related to IBS. By blocking these receptors, alosetron is able to effectively control IBS.
Alosetron is a potent and selective 5-HT<sub>3</sub> receptor antagonist. 5-HT<sub>3</sub> receptors are nonselective cation channels that are extensively distributed on enteric neurons in the human gastrointestinal tract, as well as other peripheral and central locations. Activation of these channels and the resulting neuronal depolarization affect the regulation of visceral pain, colonic transit and gastrointestinal secretions, processes that relate to the pathophysiology of irritable bowel syndrome (IBS). 5-HT<sub>3</sub> receptor antagonists such as alosetron inhibit activation of non-selective cation channels which results in the modulation of serotonin-sensitive GI motor and sensory processes.
Hepatic, via microsomal cytochrome P450 (CYP)
Alosetron has known human metabolites that include 6-hydroxy-5-methyl-2-[(5-methyl-2-oxo-1,3-dihydroimidazol-4-yl)methyl]-3,4-dihydropyrido[4,3-b]indol-1-one and 6-Hydroxy-5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-3,4-dihydropyrido[4,3-b]indol-1-one.
13Z9HTH115
ALOSETRON
Mechanisms of Action [MoA] - Serotonin 3 Receptor Antagonists
Established Pharmacologic Class [EPC] - Serotonin-3 Receptor Antagonist
Alosetron is a Serotonin-3 Receptor Antagonist. The mechanism of action of alosetron is as a Serotonin 3 Receptor Antagonist.
122852-42-0DTXSID6044278CHEMBL1110CHEBI:253342ALOSETRON
Drugs used for their effects on the gastrointestinal system, as to control gastric acidity, regulate gastrointestinal motility and water flow, and improve digestion.
Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or SEROTONIN RECEPTOR AGONISTS.
50-60 %
Renal elimination of unchanged alosetron accounts for only 6% of the dose. Alosetron is extensively metabolized in humans.
65 to 95 L
600 mL/min
용도Anti-emetic.
정의ChEBI: A pyrido[4,3-b]indole compound having a 5-methyl-1H-imidazol-4-ylmethyl group at the 2-position.